Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/COL16A1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/COL16A1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/COL16A1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/COL16A1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000704420 | Thyroid | PTC | cell-substrate junction assembly | 62/5968 | 95/18723 | 2.28e-11 | 8.76e-10 | 62 |
GO:004804119 | Thyroid | PTC | focal adhesion assembly | 56/5968 | 87/18723 | 4.63e-10 | 1.48e-08 | 56 |
GO:0150116111 | Thyroid | PTC | regulation of cell-substrate junction organization | 48/5968 | 71/18723 | 6.71e-10 | 2.04e-08 | 48 |
GO:0010810112 | Thyroid | PTC | regulation of cell-substrate adhesion | 113/5968 | 221/18723 | 1.87e-09 | 5.28e-08 | 113 |
GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
GO:0051893111 | Thyroid | PTC | regulation of focal adhesion assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:0090109111 | Thyroid | PTC | regulation of cell-substrate junction assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:000195220 | Thyroid | PTC | regulation of cell-matrix adhesion | 69/5968 | 128/18723 | 1.92e-07 | 3.51e-06 | 69 |
GO:0010811112 | Thyroid | PTC | positive regulation of cell-substrate adhesion | 65/5968 | 123/18723 | 1.10e-06 | 1.62e-05 | 65 |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:000716020 | Thyroid | PTC | cell-matrix adhesion | 109/5968 | 233/18723 | 1.28e-06 | 1.84e-05 | 109 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:015011717 | Thyroid | PTC | positive regulation of cell-substrate junction organization | 23/5968 | 33/18723 | 9.16e-06 | 1.04e-04 | 23 |
GO:000722918 | Thyroid | PTC | integrin-mediated signaling pathway | 55/5968 | 107/18723 | 2.07e-05 | 2.08e-04 | 55 |
GO:004320015 | Thyroid | PTC | response to amino acid | 58/5968 | 116/18723 | 3.59e-05 | 3.36e-04 | 58 |
GO:005189410 | Thyroid | PTC | positive regulation of focal adhesion assembly | 19/5968 | 28/18723 | 9.95e-05 | 8.15e-04 | 19 |
GO:007122914 | Thyroid | PTC | cellular response to acid chemical | 42/5968 | 80/18723 | 1.02e-04 | 8.25e-04 | 42 |
GO:0045785112 | Thyroid | PTC | positive regulation of cell adhesion | 176/5968 | 437/18723 | 1.10e-04 | 8.83e-04 | 176 |
GO:000195420 | Thyroid | PTC | positive regulation of cell-matrix adhesion | 32/5968 | 58/18723 | 2.01e-04 | 1.50e-03 | 32 |
GO:007123014 | Thyroid | PTC | cellular response to amino acid stimulus | 37/5968 | 71/18723 | 3.13e-04 | 2.17e-03 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COL16A1 | SNV | Missense_Mutation | | c.2224G>T | p.Gly742Trp | p.G742W | Q07092 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
COL16A1 | SNV | Missense_Mutation | novel | c.2005N>G | p.Pro669Ala | p.P669A | Q07092 | protein_coding | deleterious(0.01) | possibly_damaging(0.525) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
COL16A1 | SNV | Missense_Mutation | rs573984488 | c.233N>A | p.Arg78His | p.R78H | Q07092 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
COL16A1 | SNV | Missense_Mutation | | c.2512N>T | p.Pro838Ser | p.P838S | Q07092 | protein_coding | tolerated(0.1) | benign(0.018) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
COL16A1 | SNV | Missense_Mutation | | c.3994N>A | p.Gly1332Ser | p.G1332S | Q07092 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
COL16A1 | SNV | Missense_Mutation | | c.4054G>A | p.Glu1352Lys | p.E1352K | Q07092 | protein_coding | tolerated(0.11) | possibly_damaging(0.824) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
COL16A1 | SNV | Missense_Mutation | | c.3941G>C | p.Gly1314Ala | p.G1314A | Q07092 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
COL16A1 | SNV | Missense_Mutation | | c.4303N>G | p.Asn1435Asp | p.N1435D | Q07092 | protein_coding | tolerated(0.12) | possibly_damaging(0.874) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
COL16A1 | insertion | Frame_Shift_Ins | novel | c.3043_3044insCAAGGCTGAAAGAAATGATTCTAAAATCA | p.Gly1015AlafsTer36 | p.G1015Afs*36 | Q07092 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
COL16A1 | insertion | In_Frame_Ins | novel | c.468_469insCCTTGGGCT | p.Cys156_Ile157insProTrpAla | p.C156_I157insPWA | Q07092 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |